2013 Press Releases

Keyword Search
 
DateTitle  
20-Dec-2013ERYTECH announces the decision of USPTO to extend the additional exclusivity period of its core process patent to almost 4 years
ERYTECH (NYSE Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces its received final notification of allowance for the granting of its core process patent in the United States in which the term of exclusivity has been further extended from two to almost four years. This patent entitled “Lysis/Resealing Process and Device for Incorporating an Acti... 
Download PDFPrinter Friendly Version
06-Dec-2013ERYTECH announces two presentations at 55th ASH annual meeting and exposition in New Orleans
ERYTECH announces two presentations at 55th ASH annual meeting and exposition in New Orleans December 06, 2013 02:30 AM Eastern Standard Time LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that data related to the Company’s lead product GR... 
Download PDFPrinter Friendly Version
12-Nov-2013ERYTECH announces positive DSMB review of its Phase IIb study in Acute Myeloid Leukemia
ERYTECH Announces Positive DSMB Review of its Phase IIb Study in Acute Myeloid Leukemia Review of safety data of first 30 patients treated Unanimous recommendation to pursue study without modification First large scale study with an asparaginase product in this patient population November 12, 2013 12:00 PM Eastern Standard Time LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH Pharma (Paris:ERYP) (NYSE Euronext Paris: FR00114711... 
Download PDFPrinter Friendly Version
05-Nov-2013ERYTECH provides financial update for Q3 2013
ERYTECH Provides Financial Update for Q3 2013 Regulatory News: ERYTECH (Paris:ERYP) (NYSE Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces today its cash position and its revenues for the third quarter of 2013. During the third quarter of fiscal year 2013, ERYTECH did not report any income from activities. Total revenues for the year to date are amo... 
Download PDFPrinter Friendly Version
16-Sep-2013ERYTECH announces the granting of its core process patent in the United States with two additional years of exclusivity
ERYTECH Announces the Granting of Its Core Process Patent in the United States with Two Additional Years of Exclusivity Core process patent granted in the USA with 2 years extension of term Core technology and products protected until 2027 which could be extended to 2032 Patent now delivered in Europe, Japan, China, Australia, Hong-Kong and the USA ERYTECH’s intellectual property protected by 12 patent families worldwide September 16, ... 
Download PDFPrinter Friendly Version
10-Sep-2013ERYTECH completes enrollment in its Phase III study in Acute Lymphoblastic Leukemia
ERYTECH Completes Enrollment in Its Phase III Study in Acute Lymphoblastic Leukemia Randomized controlled pivotal study with 80 patients treated 58 investigator sites in various European countries (France, Belgium, Spain) Results to be available in Q3 2014 Last step before launch of the registration of GRASPA® in Europe September 10, 2013 12:00 PM Eastern Daylight Time LYON, France--(BUSINESS WIRE)--Regulatory News : ERYT... 
Download PDFPrinter Friendly Version
28-Aug-2013ERYTECH : rapport d’activité et résultats financiers du 1er semestre 2013
ERYTECH : rapport d’activité et résultats financiers du 1er semestre 2013 Solides performances opérationnelles et bonne progression des programmes cliniques Niveau de trésorerie élevé suite au succès de l’introduction en bourse et gestion rigoureuse des dépenses Solide news flow à venir August 28, 2013 12:19 PM Eastern Daylight Time LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH (Paris:ERYP) (NYSE Euronext P... 
Download PDFPrinter Friendly Version
18-Jul-2013ERYTECH provides financial update for Q2 2013
ERYTECH Provides Financial Update for Q2 2013 Cash balance of € 18.6 million on June 30 2013 Regulatory News : ERYTECH (Paris:ERYP) (NYSE Euronext Paris : FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announced today its cash position and its revenues for the second quarter of 2013. On June 30 2013, ERYTECH’s cash and cash equivalents amounted to € 18.6 million. As... 
Download PDFPrinter Friendly Version
04-Jul-2013ERYTECH Pharma announces fast take-off of its Phase IIb study in Acute Myeloid Leukemia
ERYTECH Announces Fast Take-off of Its Phase IIb Study in Acute Myeloid Leukemia 100% Of French Sites Authorized to Participate in the Study, More Than 50% of Which Are Open for Patient Enrollment Already 10% of Patients Enrolled in the Study Opening of Additional European Centers Forthcoming to Further Accelerate Patient Recruitment July 04, 2013 02:00 AM Eastern Daylight Time LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH (... 
Download PDFPrinter Friendly Version
03-Jun-2013ERYTECH Pharma provides financial update for Q1 2013
ERYTECH provides financial update for Q1 2013             RELEASE 03 JUN 2013 19:17 CET  Regulatory News:  ERYTECH, (Paris:ERYP) (NYSE Euronext Paris : FR0011471135 - ERYP) a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announce... 
Download PDFPrinter Friendly Version
30-Apr-2013ERYTECH’s IPO a remarkable success, raising €17.7 million
ERYTECH’s IPO a remarkable success, raising €17.7 million The company’s capital increased by nearly €28 million through: IPO (OPO & GP) raising €16.7 million Subscription in compensation for debts of nearly €1 million Conversion of convertible bonds for a total of €10 million, including the acquisition of a stake by Recordati – Orphan Europe Offer price set in the middle of the indicative range at €11.60 Regulatory News: ERYTECH (Paris... 
Download PDFPrinter Friendly Version
18-Apr-2013ERYTECH Announces its IPO on NYSE Euronext Paris Regulated Market
ERYTECH Announces its IPO on NYSE Euronext Paris Regulated Market Regulatory News: This document may not be published, distributed or circulated, either directly or indirectly, in the United States, Canada, Australia, Italy or Japan ERYTECH (Paris:ERYP), a French biopharmaceutical company that designs innovative treatments for acute leukaemia and other oncology indications with unmet medical needs, today announces that the French market regulator Autorité des Marchés Financiers (AMF) gra... 
Download PDFPrinter Friendly Version
03-Apr-2013ERYTECH Pharma receives FDA IND clearance to initiate a clinical study in Acute Lymphoblastic Leukemia in the U.S.
ERYTECH Pharma Receives FDA IND Clearance to Initiate a Clinical Study in Acute Lymphoblastic Leukemia in the U.S. April 03, 2013 07:58 AM Eastern Daylight Time LYON, France & PHILADELPHIA--(BUSINESS WIRE)--ERYTECH Pharma SA announced today that it has received clearance of its Investigational New Drug (IND) Application from the United States Food and Drug Administration (FDA) to initiate a Phase I clinical trial of its product ERYASP®, L-asparaginase loaded erythrocytes, in pati... 
Download PDFPrinter Friendly Version
Top